GRAIL (NASDAQ:GRAL) Shares Gap Down – Time to Sell?

GRAIL, Inc. (NASDAQ:GRAL)’s share price gapped down before the market opened on Friday . The stock had previously closed at $101.53, but opened at $49.66. GRAIL shares last traded at $53.3090, with a volume of 3,450,288 shares.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Q4 results beat expectations: GRAIL reported EPS above estimates, U.S. Galleri revenue grew ~26% to $136.8M, sold >185k tests in 2025, completed FDA PMA submission and says it has cash runway into 2030 — supports commercial progress and near‑term liquidity. GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: NHS‑Galleri showed clinically meaningful secondary signals: topline reported a substantial reduction in stage IV diagnoses, increased stage I‑II detection and a four‑fold higher cancer detection rate — these findings could support downstream regulatory/commercial arguments despite the primary miss. Landmark NHS-Galleri Trial Demonstrates …
• Positive Sentiment: Analyst support: Robert W. Baird issued an Outperform rating, which may cushion downside for some investors. GRAIL Earns Outperform Rating from Analysts at Robert W. Baird
• Neutral Sentiment: Operational updates: company completed analysis of PATHFINDER 2 and announced U.S. sales‑force expansion — supportive for commercialization but not immediately dispositive for valuation. GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Primary endpoint missed: the trial did not achieve a statistically significant combined reduction in stage III‑IV cancers — the headline miss triggered broad investor sell‑off and drove the sharp share decline. Grail shares plunge after major cancer screening trial misses main goal
• Negative Sentiment: Market reaction and headlines: multiple outlets report the trial “failed to show reduction in late‑stage diagnoses,” amplifying negative sentiment and heavy trading volume — short‑term liquidity and sentiment risk elevated. Grail shares plunge on mixed cancer trial data and steep losses
• Negative Sentiment: Legal/claims risk: a securities‑law firm has opened an investigation into potential shareholder claims, which can increase headline risk and legal uncertainty. Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GRAL. TD Cowen initiated coverage on shares of GRAIL in a research note on Thursday. They set a “hold” rating and a $114.00 price objective on the stock. Morgan Stanley lifted their price target on shares of GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group set a $80.00 price target on GRAIL in a research note on Friday. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GRAIL currently has an average rating of “Hold” and a consensus price target of $98.50.

GRAIL Stock Performance

The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -4.44 and a beta of 4.52. The business’s 50 day moving average price is $97.42 and its 200-day moving average price is $75.82.

GRAIL (NASDAQ:GRAL) last released its earnings results on Thursday, February 19th. The company reported ($2.44) EPS for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%.The company had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. On average, analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Institutional Trading of GRAIL

A number of institutional investors and hedge funds have recently modified their holdings of the business. N.E.W. Advisory Services LLC bought a new position in GRAIL in the 4th quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new position in GRAIL during the 4th quarter valued at about $31,000. Comerica Bank raised its position in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Intesa Sanpaolo S.p.A. acquired a new stake in shares of GRAIL in the 4th quarter worth approximately $44,000. Finally, Ankerstar Wealth LLC bought a new position in shares of GRAIL in the fourth quarter valued at approximately $45,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.